Title:
BENZIMIDAZOLE COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/156788
Kind Code:
A1
Abstract:
Provided are a new compound for effectively inhibiting the activity of IRAK4, a preparation method therefor, and the use thereof in the preparation of a drug, wherein the new compound is a compound as represented by formula I, and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof.
Inventors:
ZHANG XUEJUN (CN)
ZANG YANG (CN)
WEI WENJUN (CN)
LV JIANBO (CN)
YANG CHENGBING (CN)
LI YANG (CN)
ZHANG BO (CN)
CHANG SHAOHUA (CN)
LI LIE (CN)
YANG JUN (CN)
ZANG YANG (CN)
WEI WENJUN (CN)
LV JIANBO (CN)
YANG CHENGBING (CN)
LI YANG (CN)
ZHANG BO (CN)
CHANG SHAOHUA (CN)
LI LIE (CN)
YANG JUN (CN)
Application Number:
PCT/CN2022/073320
Publication Date:
July 28, 2022
Filing Date:
January 21, 2022
Export Citation:
Assignee:
WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN)
International Classes:
C07D413/14; A61K31/4184; A61K31/443; A61K31/5375; A61P35/00; A61P35/02; A61P37/02; C07D247/02; C07D403/14; C07D405/14
Domestic Patent References:
| WO2018060174A1 | 2018-04-05 | |||
| WO2017207340A1 | 2017-12-07 |
Foreign References:
| CN112480101A | 2021-03-12 |
Other References:
CHEN YUN, NING YI, BAI GANG, TONG LINJIANG, ZHANG TAO, ZHOU JINPEI, ZHANG HUIBIN, XIE HUA, DING JIAN, DUAN WENHU: "Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs", ACS MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 1, 14 January 2021 (2021-01-14), US , pages 82 - 87, XP055952216, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.0c00474
Attorney, Agent or Firm:
ZHIFAN & PARTNERS (CN)
Download PDF: